von Willebrand Factor, Soluble P-Selectin, Tissue Plasminogen Activator and Plasminogen Activator Inhibitor in Atherosclerosis

A D Blann; M Dobrotova; P Kubisz; C N McCollum

doi:10.1055/s-0038-1649788

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 1995; 74(02): 626-630
DOI: 10.1055/s-0038-1649788

Original Article

Clinical Studies

Schattauer GmbH Stuttgart

von Willebrand Factor, Soluble P-Selectin, Tissue Plasminogen Activator and Plasminogen Activator Inhibitor in Atherosclerosis

A D Blann

¹The Department of Surgery, University Hospital of South Manchester, Manchester, UK

,

M Dobrotova

²The Department of Haematology and Blood Transfusion, Jessenius Medical Faculty, Comenius University, Martin’s Faculty Hospital, Martin, Slovak Republic

,

P Kubisz

²The Department of Haematology and Blood Transfusion, Jessenius Medical Faculty, Comenius University, Martin’s Faculty Hospital, Martin, Slovak Republic

,

C N McCollum

¹The Department of Surgery, University Hospital of South Manchester, Manchester, UK

› Institutsangaben

Abstract

als PDF herunterladen

Summary

Tissue plasminogen activator antigen (tPA), plasminogen activator inhibitor antigen (PAI-1), soluble P-selectin and von Willebrand factor antigen (vWf) were measured by ELISA in 41 patients with peripheral vascular disease (PVD), 41 with ischaemic heart disease (IHD) and in 46 age and sex matched asymptomatic controls. Increased vWf was found in patients with IHD (p = 0.0002) and in patients with PVD (p = 0.0011) relative to the controls but levels did not differ between the two patients groups. Raised tPA found in both PVD (p = 0.0006) and IHD (p = 0.0061) compared to the controls also failed to differentiate the two groups of patients. Soluble P-selectin was also raised in both groups (p = 0.003 in IHD and p = 0.0102 in PVD) with no difference between the groups. There were no differences in levels of PAI-1 between the groups. In the subjects taken as a whole, there were significant Spearman’s correlations between tPA and vWf (r = 0.37, p <0.001), tPA and triglycerides (r = 0.38, p <0.001), tPA and P-selectin (r = 0.19, p = 0.032), vWf and age (r = 0.25, p = 0.005) and inversely between vWf and HDL (r = -0.25, p = 0.006). These data support the concept that increased levels of tPA may be important in atherosclerosis, and indicate that soluble P-selectin may be useful in further analysis of the role of platelets and the endothelial cell in this disease.

PDF (404 kb)

Referenzen

References
1 Borsum T. Biochemical properties of vascular endothelial cells. Virchows Archiv B Cell Pathol 1991; 60: 279-286
2 Hekman CM, Loskutoff DJ. Fibrinolytic pathways and the endothelium. Seminars Thromb Haemost 1987; 13: 514-527
3 Loscalzo J, Braunwald E. Tissue plasminogen activator. N Engl J Med 1988; 319: 925-931
4 Dawson S, Henney A. The status of PAI-1 as a risk factor for arterial and thrombotic disease: A review. Atherosclerosis 1992; 95: 105-17
5 Nilsson TK, Boman K, Bjerle P, Hallamns G, Hellsten G. von Willebrand factor and fibrinolytic variables are differently affected in the insulin resistance syndrome. J Int Med 1994; 235: 419-423
6 Hamsten A, Faire U de, Walldius G, Dahlen G, Szamosi A, Landou C, Blomback M, Wiman B. Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction. Lancet 1987; 2: 3-8
7 Blann AD. von Willebrand factor and the endothelium in vascular disease. Br J Biomed Sci 1993; 50: 125-134
8 Blann AD, McCollum CN. Circulating endothelial cell/leukocyte adhesion molecules in atherosclerosis. Thromb Haemost 1994; 72: 151-154
9 Wagner DD. The Weibel-Palade body: the storage granule for von Willebrand factor and P-selectin. Thromb Haemost 1993; 70: 105-110
10 Gearing AJ H, Newman W. Circulating adhesion molecules in disease. Immunol Today 1993; 14: 506-512
11 Springer TA. Adhesion receptors of the immune system. Nature 1990; 346: 425-434
12 Geng JG, Bevilacqua MP, Moore KL, McIntyre TM, Prescott SM, Kim JM, Bliss GA, Zimmerman GA, McEver RP. Rapid neutrophil adhesion to activated endothelium mediated by GMP-140. Nature 1990; 313: 757-760
13 Gralnick HR. von Willebrand’s disease. In: Disorders of Haemostasis. Ratnoff OD, Forbes CD. (eds) Philidelphia: WB Saunders; 1991: 203-244
14 Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801-809
15 Mustard JF, Packham MA. The role of blood and platelets in atherosclerosis and the complications of atherosclerosis. Thromb Diathes Haemorrh 1975; 33: 444-56
16 Fuster V, Stein B, Ambrose JA, Badimon L, Badimon JJ, Chesebro JH. Atherosclerosis plaque rupture and thrombosis; Evolving concepts. Circulation 1990; 82 Suppl (Suppl. 02) II-47-II-59
17 van Zanten GH, de Graaf S, Slootweg PJ, Heijnen HF G, Connolly TM, de Groot PG, Sixma JJ. Increased platelet deposition on atherosclerotic coronary arteries. J Clin Invest 1994; 93: 615-632
18 Seigneur M, Dufourc P, Conri C, Constans J, Mercie P, Pruvost A, Amiral J, Midy D, Baste JC, Boisseau MR. Levels of plasma thrombomodulin are increased in atheromatous arterial disease. Thrombosis Res 1993; 71: 423-431
19 Hellsten G, Boman K, Bjerle P, Blom P, Nilsson TK. Increased plasminogen activator inhibitor and tissue plasminogen activator levels in subjects with electrocardiographic abnormality indicative of ischaemic heart disease: a cross sectional study in Norsjo, Sweden. Eur Heart J 1992; 13: 57-60
20 Oseroff A, Krishnamurti C, Hassett A, Tang D, Alving B. Plasminogen activator and plasminogen activator inhibitor activities in men with coronary artery disease. J Lab Clin Med 1989; 113: 88-93
21 Speiser W, Speiser P, Minar E, Kominger C, Neissner H, Huber K, Schemthaner G, Ehringer H, Lechner K. Activation of coagulation and fibrinolysis in patients with arteriosclerosis: Relation to localisation of vessel disease and risk factors. Thrombosis Res 1990; 59: 77-88
22 Prins MH, Hirsh J. A critical review of the relationship between impaired fibrinolysis and myocardial infarction. Am Heart J 1991; 122: 545-551
23 Munkvad S, Jespersen J, ram J, Kluft C. Interrelationship between coagulant activity and tissue type plasminogen activator (t-PA) system in acute ischaemic heart disease. Possible role of the endothelium J Int Med 1990; 228: 361-366
24 Cortellaro M, Cofrancesco E, Boschetti C, Mussoni L, Donati MB, Cardillo M, Catalano M, Gabrielli L, Lombardi B, Specchia G. et al. Increased fibrin turnover and high PAI-1 activity as predictors of ischaemic events in atherosclerosis patients. A case control study The PLAT group Arteriosclerosis Thromb 1993; 13: 1412-1417
25 Kunzendorf U, Notter M, Hock H, Distler A, Diamantstein T, Walz G. T cells bind to the endothelial adhesion molecule GMP-140 (P-selectin). Transplantation 1993; 56: 1213-1217
26 Hamburger SA, McEver RP. GMP-140 mediates adhesion of stimulated platelets to neutrophils. Blood 1990; 75: 550-554
27 Parmentier S, McGregor L, Catimel B, Leung LL K, McGregor JL. Inhibition of platelet functions by a monoclonal antibody (LYP20) directed against a granule membrane glycoprotein (GMP-140/PADGEM). Blood 1991; 77: 1734-1739
28 Wong CS, Gamble JR, Skinner MP, Lucas CM, Berndt MC, Vadas MA. Adhesion protein GMP140 inhibits superoxide anion release by human neutrophils. Proc Natl Acad Sci USA 1991; 88: 2397-2401
29 Gamble JR, Skinner MP, Berndt MC, Vadas MA. Prevention of activated neutrophil adhesion to endothelium by soluble adhesion protein GMP 140. Science 1990; 249: 414-417
30 Wada H, Minamikawa K, Wakita Y, Nakase T, Kaneko T, Ohiwa M, Tamaki S, Deguchi K, Shirakawa S, Hayashi T, Suzuki K. Increased vascular endothelial cell markers in patients with disseminated intravascular coagulation. Am J Haem 1993; 44: 85-88
31 Takahashi H, Ito S, Hanano M, Wada K, Niwano H, Seki Y, Shibata A. Circulatingthrombodulin as a novel endothelial cell marker: Comparison of its behaviour with von Willebrand factor and tissue type plasminogen activator. Am J Haem 1992; 41: 32-39
32 Wada H, Keneko T, Ohiwa Tanigawa M, Hayashi T, Tamaki S, Minami N, Deguchi K, Suziki K, Nakaon T, Shirakawa S. Increased levels of vascular endothelial cell markers in thrombotic thrombocytopenic purpura. Am J Haem 1993; 44: 101-105
33 Lupu F, Bergonzelli GE, Heim DA, Cousin E, Genton CY, Bachmann F, Kruithof EK O. Localisation and production of plasminogen activator inhibitor-1 in human healthy and atherosclerosis arteries. Arteriosclerosis Thromb 1993; 13: 1090-1100
34 Wang DL, Pan YT, Wang JJ, Cheng CH, Liu CY. Demonstration of a functionally active tPA-like plasminogen activator in human platelets. Thromb Haemost 1994; 71: 493-498
35 Torr-Brown SR, Sobel BE. Attenuation of thrombolysis by release of plasminogen activator inhibitor type-1 from platelets. Thrombosis Res 1993; 413-421
36 Blann AD, Tabemer DA. A reliable marker of endothelial cell dysfunction: does it exist. Br J Haem 1995; 90: 244-248
37 Collins PW, Macey MG, Cahill MR, Newland AC. von Willebrand factor release and P-selectin expression is stimulated by thrombin and trypsin but not IL-1 in cultured human endothelial cells. Thromb Haemost 1993; 70: 346-350
38 Miller GJ, Miller NE. Plasma high density lipoprotein concentration and development of ischaemic heart disease. Lancet 1975; 1: 16-19
39 Gershlick AH. Are there markers of the blood-vessel wall interaction and of thrombus formation that can be used clinically. Circulation 1990; 81 Suppl (Suppl. 01) I-28-I-34